Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-6 of 207 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 1-6 of 207 studies
-
Genetic TherapyEnrolling
Study to evaluate VX-522 in adults 18 years and older with cystic fibrosis. , protocol number Vertex VX21-522-001 SADThis study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA) therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy.
-
Age:
18 Years to 65 Years
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
8
-
Length of Participation:
6 months
-
-
Restore CFTR ProteinEnrolling
Study of Trikafta® in people with CF ages 12 years and older who have an N1303K CFTR mutation , protocol number N1303K Sub-StudyThis study will look at the effectiveness of Trikafta, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta® and a least one of these mutations must be N1303K.
-
Age:
12 Years and Older
-
Mutation(s):
No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
86 days
-
-
Anti-InfectiveEnrolling
Study of ARV-1801 (ACG-701) for the treatment of pulmonary exacerbations in CF patients 12 years of age or older. , protocol number Aceragen ARV-1801This study will evaluate the efficacy and safety of the study drug ARV-1801, an oral drug intended to treat infections in the lung. The study also will evaluate how the body process the drug.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
28 days
-
-
Nutritional-GIEnrolling
Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis , protocol number AbbVie M21-432This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
3
-
Length of Participation:
142 days
-
-
ObservationalEnrolling
MAYFLOWERS: Study of pregnancy in women with cystic fibrosis , protocol number MAYFLOWERS-OB-20This observational study will evaluate the effects of CFTR modulators on women with CF during and after pregnancy. CFTR modulators are intended to help CFTR protein function closer to normal.
-
Age:
16 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
9
-
Length of Participation:
35 months
-
-
OtherEnrolling
Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
49 days
-
Showing 1-6 of 207 studies
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More